Biotech · Private company · San Francisco, CA, US
Revel Pharmaceuticals Inc.
Track this companyFree. Adds Revel Pharmaceuticals Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards5
- Development of enzymatic tools for rapid measurement of Advanced Glycation and Lipoxidation End Product-protein adductsFiscal year 2026 · $923.6KNIH RePORTER 5R44AG084351-03 · fetched Nov 12, 2026
- Development of advanced glycation end product (AGE)-breaking enzymes as a novel therapy for the treatment of diabetic retinopathyFiscal year 2025 · $358.1KNIH RePORTER 1R43EY036695-01A1 · fetched Nov 12, 2026
- Development of enzymatic tools for rapid measurement of Advanced Glycation and Lipoxidation End Product-protein adductsFiscal year 2025 · $1.4MNIH RePORTER 2R44AG084351-02 · fetched Nov 12, 2026
- Development of advanced glycation end product (AGE)-breaking enzymes as a novel therapy for the treatment of diabetic kidney diseaseFiscal year 2024 · $324KNIH RePORTER 1R43DK137624-01A1 · fetched Nov 12, 2026
- An enzyme-based assay for the detection of carboxyethyl lysine-protein adductsFiscal year 2024 · $346.8KNIH RePORTER 1R43GM154502-01 · fetched Nov 12, 2026